• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

18.83 -0.18 (-0.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,892,053
Open 18.79
Bid (Size) 18.84 (100)
Ask (Size) 18.99 (800)
Prev. Close 19.01
Today's Range 18.55 - 19.24
52wk Range 15.55 - 36.91
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗
January 06, 2026
Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital. 
Via The Motley Fool
Topics Stocks
News headline image
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From Summit Therapeutics
Via Business Wire

Performance

YTD
+7.5%
+7.5%
1 Month
+10.6%
+10.6%
3 Month
-16.9%
-16.9%
6 Month
-27.2%
-27.2%
1 Year
+0.1%
+0.1%

More News

Read More
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40% ↗
October 19, 2025
Via Stocktwits
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
December 11, 2025
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
Up Nearly 400% This Year, Can Oklo Stock Still Rise Higher? ↗
December 10, 2025
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗
December 09, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? ↗
December 05, 2025
Via The Motley Fool
News headline image
Don't Buy Summit Therapeutics Until This Big Thing Happen ↗
December 03, 2025
Via The Motley Fool
News headline image
2 Monster Stocks in the Making to Buy and Hold ↗
December 02, 2025
Via The Motley Fool
News headline image
Summit SMMT Q3 2025 Earnings Call Transcript ↗
November 27, 2025
Via The Motley Fool
Topics Earnings
News headline image
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
November 07, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Present at Upcoming Investor Conferences
November 04, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
October 31, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Alpha Buying: When Insiders Buy Big & Why It Works in Every Market ↗
October 30, 2025
Via Benzinga
News headline image
Why Wall Street Is Backing These 3 Comeback Stocks ↗
October 28, 2025
Via MarketBeat
News headline image
1 Monster Stock in the Making to Buy and Hold ↗
October 27, 2025
Via The Motley Fool
News headline image
Summit Therapeutics: A Risky Bet in the Biotech Arena? ↗
October 24, 2025
Via The Motley Fool
News headline image
Summit Therapeutics Raises $500 Million in Private Placement
October 22, 2025
From Summit Therapeutics
Via Business Wire
News headline image
What's Going On With Summit Therapeutics Stock On Monday? ↗
October 20, 2025
Via Benzinga
News headline image
Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗
October 20, 2025
Via Benzinga
News headline image
Summit Therapeutics Inc (NASDAQ:SMMT) Reports Wider-Than-Expected Q3 2025 Loss ↗
October 20, 2025
Via Chartmill
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
October 20, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Earnings Scheduled For October 20, 2025 ↗
October 20, 2025
Via Benzinga

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 18.83
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 01/08/26 04:00 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.83B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap